| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Property and equipment, net | 5,175 | |||
| Short-term investments (amortized cost of 307,394) | 307,610 | |||
| Prepaid expenses and other current assets | 11,015 | |||
| Refundable income taxes | 1,793 | |||
| Grants receivable | 475 | |||
| Cash and cash equivalents | 207,820 | |||
| Research and development tax credits receivable | 280 | |||
| Total current assets | 528,993 | |||
| Restricted cash | 319 | |||
| Other assets | 898 | |||
| Right of use assets | 5,129 | |||
| Long-term investments (amortized cost of 74,475) | 74,614 | |||
| Research and development tax credits receivable, net of current portion | 7,955 | |||
| Total assets | 623,083 | |||
| Other accrued expenses | 796 | |||
| Lease liabilities | 1,516 | |||
| Accrued personnel expenses | 23,774 | |||
| Deferred income | 1,477 | |||
| Accounts payable | 6,249 | |||
| Accrued clinical trial costs | 36,462 | |||
| Total current liabilities | 70,274 | |||
| Unrecognized tax benefits | 48,790 | |||
| Lease liabilities, net of current portion | 3,612 | |||
| Grants repayable, net of current portion | 6,606 | |||
| Total liabilities | 129,282 | |||
| Accumulated deficit | -123,123 | |||
| Common stock, 0.001 par value 150,000,000 shares authorized at march 31, 2025 and december 31, 2024 38,271,682 and 36,598,043 shares issued and outstanding, respectively | 44 | |||
| Additional paid-in capital | 633,070 | |||
| Accumulated other comprehensive loss | -16,190 | |||
| Total stockholders equity | 493,801 | |||
| Total liabilities and stockholders equity | 623,083 | |||
iTeos Therapeutics, Inc. (ITOS)
iTeos Therapeutics, Inc. (ITOS)